Teriparatide
PTH (1-34) / Forteo
Teriparatide (PTH (1-34) / Forteo) is a healing & recovery research compound. The active fragment of parathyroid hormone — intermittent daily dosing paradoxically stimulates osteoblasts and builds new bone (continuous PTH does the opposite).
Teriparatide quick facts
| Reported research dose | 20mcg |
| Route | Subq |
| Frequency | 1x Daily |
| Half-life | ~1 hr |
| Forms | Injectable |
| Evidence level | FDA-approved (osteoporosis); human |
Bone-building, not a GLP-1. The daily-pulse pattern is what makes it anabolic instead of catabolic.
How Teriparatide works
The active fragment of parathyroid hormone — intermittent daily dosing paradoxically stimulates osteoblasts and builds new bone (continuous PTH does the opposite).
Proposed benefits
Researched for soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
Can you actually get Teriparatide?
A specialist osteoporosis injectable (Forteo). Prescribed by an endocrinologist or rheumatologist, not through telehealth.
Recombinant parathyroid hormone (1-34) and the first anabolic osteoporosis drug — it builds new bone rather than slowing the loss of old bone, which is what every bisphosphonate does.
Get the label history right, because the internet has it wrong in both directions. The osteosarcoma boxed warning was REMOVED on 16 November 2020, after registry-linked observational studies found no increased incidence in treated patients; what replaced it says the rat finding stands and the human signal does not. The two-year lifetime cap became conditional at the same time. The number that actually needs watching is calcium — a transient rise after each dose is the expected pharmacology, and a persistent one is not.
Order these through my Marek link →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Teriparatide
Graded by what exists behind each claim.
✅ Clinically validated
- FDA-approved with major randomized data — the pivotal Neer trial showed a 65% reduction in vertebral fractures. Two decades of clinical use since.
- The rat osteosarcoma signal that produced the original black-box warning was removed from the label in 2020 after long-term human surveillance found no increased risk. That reversal is a good example of a preclinical finding that did not transfer.
📊 Correlative data
- Two decades of prescription use in severe osteoporosis, which is where the real-world record lives. It is limited to 24 months of lifetime use in most guidelines — originally because of the rat osteosarcoma signal, and retained afterwards because the anabolic effect plateaus. No community availability, so there is no anecdotal layer here at all.
🧪 Theoretical / extrapolated
- Recombinant PTH (1-34). The dosing pattern determines the direction of the effect: intermittent daily injection stimulates osteoblasts and builds bone, while continuous elevation — as in hyperparathyroidism — resorbs it.
- That is one of the cleanest examples in endocrinology of pulsatility mattering more than dose, and the same principle recurs across the GH secretagogues on this site.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Teriparatide actually does
Teriparatide is the first 34 amino acids of the 84-residue human parathyroid hormone — the biologically active N-terminal region, identical in sequence to the native hormone Forteo label. It is not an analog in the way most peptides on this site are analogs. It is a fragment, and the fragment is the whole receptor-binding half of the molecule.
The mechanism is a paradox, and the paradox is the drug. Chronically elevated parathyroid hormone — primary hyperparathyroidism — destroys bone. The same hormone given once a day builds it. One receptor, one ligand, opposite net outcomes, and the only variable is the shape of the exposure curve over 24 hours. There is no other drug in the Vault whose direction of effect is set by its pharmacokinetics rather than by its dose.
Why time-course flips the sign. PTH1R is a class B G-protein-coupled receptor on osteoblasts and osteocytes. A brief pulse raises cyclic AMP in the osteoblast lineage, suppresses osteocyte sclerostin, releases the brake sclerostin holds on Wnt signaling, and — critically — reduces osteoblast apoptosis, so the existing population of bone-forming cells survives longer and keeps working. Sustained occupancy does something different: it holds RANKL expression up and osteoprotegerin down for long enough that osteoclastogenesis wins. The pulse recruits builders; the plateau recruits demolishers.
Which means the half-life is not a footnote on this page, it is the active ingredient. The label puts the subcutaneous half-life at approximately 1 hour, peak serum concentration at about 30 minutes, and absolute bioavailability at approximately 95% Forteo label. Do the arithmetic: five half-lives after a 30-minute peak puts serum back to baseline inside six hours, so bone sees pharmacological PTH for roughly a quarter of the day and physiological PTH for the rest. A longer-acting version of this molecule would not be a better drug. It would be hyperparathyroidism.
The consequence nobody states. Because the anabolic signal is delivered by a spike rather than by an average concentration, missing a dose is not the same as halving one, and splitting a 20 mcg dose into two 10 mcg doses is not a conservative choice — it is a different pharmacology. Every trial below dosed once daily.
Cell, rodent, human — and where it stops
Step one, the pivotal fracture trial, which is where this drug earned its place. 1,637 postmenopausal women with prior vertebral fractures, randomized to placebo or once-daily subcutaneous PTH(1-34) at 20 or 40 mcg. New vertebral fractures occurred in 14% of the placebo group, 5% at 20 mcg and 4% at 40 mcg, with dose-dependent increases in bone mineral density; the commonest side effects were nausea and headache Neer 2001.
Read the 20-versus-40 comparison, because it is the reason the approved dose is the lower one. Doubling the dose moved vertebral fracture incidence from 5% to 4% — one percentage point — while raising the hypercalcemia and tolerability burden. That is a flat top to the dose-response curve, and it is the single best argument against the instinct that more of an anabolic agent must be better.
Step two, the class comparison, which is where teriparatide stops being the automatic answer. A systematic review and network meta-analysis of PTH1 receptor agonists found both teriparatide and abaloparatide reduce vertebral and non-vertebral fractures against placebo, with abaloparatide showing an advantage over teriparatide for non-vertebral fractures and comparable safety Beaudart 2025. Abaloparatide's own placebo-controlled trial is in the same estate Miller 2016. Non-vertebral fracture is the endpoint that includes hip, which is the endpoint that changes how people live.
Step three, the pharmacokinetic bridge, which is unusually well characterized because biosimilars had to prove it. 105 subjects, healthy men and postmenopausal women, single 20 mcg subcutaneous injections on consecutive days in a three-period crossover comparing a biosimilar against both EU- and US-approved reference products. The 90% confidence intervals for the geometric mean ratios of Cmax, AUC0-t and AUC0-∞ all fell inside 80.00% to 125.00%, with comparable serum calcium response and no meaningful immunogenicity difference Fenwick 2023. That is a rare thing on this site: a peptide whose exposure has been measured to regulatory standard in more than one product.
Step four, the osteosarcoma story, which is the best worked example of a warning being written and then unwritten. A phase 3 program was terminated after preclinical osteosarcoma findings in rats; the drug was later approved with a boxed warning and use restrictions; subsequent real-world studies found no increased osteosarcoma risk, and the boxed warning was removed in 2020 label updates Krege 2022. The current label retains a narrower instruction — avoid in people with increased baseline osteosarcoma risk, including open epiphyses and prior radiation therapy Forteo label.
The obstacles. (1) The pivotal evidence is in postmenopausal women with existing vertebral fractures; that is not the population using it for fracture healing or athletic recovery. (2) There is no randomized trial showing accelerated healing of an ordinary fracture in an otherwise healthy adult. (3) The label still frames use beyond two years as a decision for people who remain at high fracture risk Forteo label. (4) Every number above comes from once-daily subcutaneous dosing and none of it transfers to any other schedule.
Teriparatide pharmacokinetics — how much of it actually gets in
Teriparatide has the most completely published pharmacokinetics of anything in this cohort, and unusually the numbers are the mechanism rather than a constraint on it.
The published curve. Absolute bioavailability after subcutaneous injection is approximately 95% pooled across 20, 40 and 80 mcg doses; peak serum concentration is reached about 30 minutes after injection; the apparent half-life is approximately 1 hour subcutaneously; and systemic clearance is approximately 62 L/hour in women and 94 L/hour in men Forteo label. Bioequivalence work reproduced Cmax and AUC across three products inside the standard 80–125% window Fenwick 2023.
Why 95% bioavailability is remarkable and what it tells you. Most peptides given subcutaneously lose a large fraction to peptidases in the subcutis and to lymphatic transit before reaching plasma. A 34-residue peptide arriving essentially intact means absorption is fast enough to outrun local proteolysis — and that is also why the peak is sharp. Clearance is peptidase-mediated and hepatic-renal rather than cytochrome-mediated: this molecule is cut up as protein, not oxidized as a drug, which is why no CYP interaction list exists for it.
The sex difference in clearance is a real number nobody uses. 62 L/hour in women against 94 L/hour in men Forteo label is a roughly 50% higher clearance in men at the same fixed 20 mcg dose. The dose is not weight-adjusted or sex-adjusted, so a man receives a meaningfully smaller area under the curve than a woman does from the identical pen. The pivotal fracture trial was run entirely in postmenopausal women Neer 2001, which means the efficacy evidence sits at the higher-exposure end of that split.
Oral is not merely poor, it is structurally impossible at any useful cost. A 34-residue peptide meets pepsin, trypsin, chymotrypsin and brush-border aminopeptidases before absorption, and the fraction that crossed intact would still face first-pass hepatic extraction. That is why the delivery system is a refrigerated injection pen and why every alternative route ever tried for this molecule has been about preserving the pulse, not about avoiding the needle.
What would have to be true, and how you would know it was not
Three predictions with markers, directions and windows. The second is the one that decides whether to continue; the third argues against the popular use.
1. Serum calcium should rise transiently and be back to normal at trough — and the timing of the draw is the whole test. The label's own pharmacodynamic marker in the bioequivalence work was serum calcium Fenwick 2023, and the label warns the drug may cause or worsen hypercalcemia Forteo label. Prediction: a CMP drawn at least 16 hours after a dose shows normal calcium; a persistently high trough calcium means the exposure is no longer pulsatile and the anabolic argument no longer applies. Pair it with a baseline PTH and calcium panel, because an undiagnosed primary hyperparathyroidism is the one condition in which this drug is mechanistically the wrong idea.
2. Bone formation markers should move before anything else does, and their failure to move is the early falsifier. The mechanism is osteoblast survival and modeling-based formation, so the formation marker should rise first and fastest. Prediction: osteocalcin (or P1NP where available) rises measurably by 4 to 12 weeks, well before any bone density scan could detect anything. If formation markers are flat at 3 months on correct daily dosing, the mechanism is not engaging in that person and continuing to 24 months is spending time rather than building bone. Nobody sells this as the decision point and it is the cheapest one available.
3. Against the popular use: urinary calcium and uric acid, and the fracture-healing claim that has no trial. The label reports increased urinary calcium excretion Forteo label, so a urinalysis with a stone history in the room is not optional, and uric acid belongs on the same panel. The larger prediction is negative: this compound is used off-label to speed ordinary fracture healing, and the evidence base behind it is fracture prevention in postmenopausal women with established osteoporosis Neer 2001. Prediction: in a healthy adult with a simple fracture, a 6-week course produces no detectable difference in union time against standard care. That prediction could be wrong, and the trial to settle it would be small and cheap, and it has not been done.
What nobody has tested yet
Four gaps, three of which are answerable with existing instruments.
Whether the male dose should be different. Clearance is about 50% higher in men and the dose is fixed Forteo label. Nobody has run a sex-stratified exposure-response analysis against fracture outcome, so there is no published answer to whether men are systematically under-dosed by the standard pen or whether the flat top of the dose-response curve makes it irrelevant Neer 2001.
What the optimal pulse actually looks like. Daily dosing was chosen and validated; it was never optimized against the underlying cell biology. A shorter, sharper exposure or a different interval might produce a larger sclerostin suppression per unit of calcium burden, and the experiment — formation markers against exposure shape — has never been published in humans.
Whether the abaloparatide non-vertebral advantage is a receptor difference or a trial difference. The network meta-analysis reports the advantage Beaudart 2025 but a network comparison is not a head-to-head. If the difference is real and mechanistic, it should be reproducible as a difference in cortical bone response, which is measurable and has not been the primary endpoint of a direct comparison.
Whether it does anything for a normal fracture. This is the single most common non-approved use, it has a plausible mechanism, and there is no adequately powered randomized trial of union time in otherwise healthy adults. Absence of a trial is not evidence of absence — it is an experiment that nobody has funded because the drug is off patent.
Teriparatide — its own safety story, not its class's
This compound's own risk story is a calcium story and a duration story, and the famous risk is the one that turned out to be smallest.
The osteosarcoma warning, honestly. Rats given high, lifelong doses developed osteosarcoma, a phase 3 program was stopped, the drug was approved with a boxed warning and use restrictions, and years of real-world data then found no increased osteosarcoma risk in people — leading to the boxed warning being removed in 2020 Krege 2022. What survives on the label is narrower and still worth reading: avoid in people at increased baseline osteosarcoma risk, including open epiphyses and prior radiation therapy Forteo label. Open epiphyses is the operative clause for anyone under about 25.
The risk that is actually common is orthostatic hypotension, and it is dose-timing rather than dose. The label reports transient symptomatic orthostatic hypotension in 5% of volunteers Forteo label. It clusters around the first several doses and around the sharp 30-minute peak. Injecting while seated, and staying seated for the first hour of the first few doses, is a mitigation that comes directly from the exposure curve rather than from general caution.
Hypercalcemia and urinary calcium. The drug can cause or worsen hypercalcemia and increases urinary calcium excretion, although the frequency of hypercalciuria was similar to placebo in the trials Forteo label. The population where this matters is anyone with a history of kidney stones, and the relevant fact is that calcium and vitamin D are usually co-prescribed with it — so the total calcium load is the sum of three things, not one.
The duration question, which is the one people get wrong in both directions. The label frames use beyond two years as a decision for people who remain at or return to high fracture risk Forteo label. The reason to stop is not danger; it is that the anabolic effect attenuates as resorption catches up with formation. The reason not to simply stop and walk away is that the gains are held by a treatment that ends, and the standard sequence after an anabolic agent is an antiresorptive — a decision for whoever prescribed it, and one this site cannot make.
Sources read for this page
- Neer RM, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine 2001 · PMID 11346808
- U.S. Food and Drug Administration. FORTEO (teriparatide injection) — full prescribing information. DailyMed, U.S. National Library of Medicine
- Fenwick S, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women. Osteoporosis International 2023 · PMID 36287230
- Beaudart C, et al. PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis. Osteoporosis International 2025 · PMID 40047881
- Krege JH. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.. JBMR Plus 2022 · PMID 36111201
- Miller PD. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.. JAMA 2016 · PMID 27533157
Teriparatide — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Teriparatide — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Teriparatide moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Teriparatide in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Teriparatide
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Parathyroid Hormone & Calcium | It IS a PTH analog. Hypercalcemia is the defined risk |
| Vitamin D (25-Hydroxy) | Must be replete before starting, or the drug can't work |
| Osteocalcin | Bone formation — the effect you're paying for |
| Comprehensive Metabolic Panel (CMP) | Kidney function and calcium handling |
The Bone Density & Fracture Risk panel covers these in one order — 8 markers, $299.70 with the discount applied.
Check results you already have → · All 103 markers A–Z
Teriparatide — frequently asked questions
What is Teriparatide?
Teriparatide (PTH (1-34) / Forteo) is a healing & recovery research compound. The active fragment of parathyroid hormone — intermittent daily dosing paradoxically stimulates osteoblasts and builds new bone (continuous PTH does the opposite).
Is the full Teriparatide protocol on this page?
The reported research dose is on this page, along with how Teriparatide works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Teriparatide?
Teriparatide has an approximate half-life of ~1 hr, which is part of what determines how often it's dosed.
What's the evidence behind Teriparatide?
Current evidence level: FDA-approved (osteoporosis); human. Teriparatide is offered for research purposes only and is not an approved medicine.
Teriparatide inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Teriparatide is used for
Teriparatide appears under 2 goals in the goal router.
Related Healing & Recovery compounds
Where this goes next
Teriparatide is the bone arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.